AstraZeneca PLC (ADR)
General ticker "AZN" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $283.7B (TTM average)
AstraZeneca PLC (ADR) does not follow the US Stock Market performance with the rate: -25.1%.
Estimated limits based on current volatility of 1.6%: low 162.52$, high 167.72$
Factors to consider:
- Earnings expected soon, date: 2026-10-30 bmo
- Company pays dividends (semi-annually): last record date 2026-08-07, amount 1.06$ (Y1.28%)
- Total employees count: 96100 (+1.9%) as of 2025
- Price in estimated range
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [142.11$, 203.20$]
- 2026-12-31 to 2027-12-31 estimated range: [157.92$, 222.39$]
Financial Metrics affecting the AZN estimates:
- Negative: with PPE of 19.9 at the end of fiscal year the price was high
- Positive: 4.90 < Operating cash flow per share per price, % of 5.16
- Positive: 42.26 < Shareholder equity ratio, % of 42.66 <= 49.86
- Positive: Industry earnings per price (median), % of 6.62 > 6.58
- Positive: Industry inventory ratio change (median), % of 0.50 <= 1.15
- Positive: 7.19 < Return on assets ratio (scaled to [-100,100]) of 8.25
- Positive: 22.58 < Operating profit margin, % of 23.40
- Positive: 5.56 < Industry operating cash flow per share per price (median), % of 5.61
- Positive: 14.78 < Industry operating profit margin (median), % of 24.67
- Positive: -2.60 < Investing cash flow per share per price, % of -2.41
Short-term AZN quotes
Long-term AZN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $45,811.00MM | $54,073.00MM | $58,739.00MM |
| Operating Expenses | $37,618.00MM | $44,070.00MM | $44,996.00MM |
| Operating Income | $8,193.00MM | $10,003.00MM | $13,743.00MM |
| Non-Operating Income | $-1,294.00MM | $-1,312.00MM | $-1,341.00MM |
| Interest Expense | $1,589.00MM | $1,682.00MM | $1,694.00MM |
| R&D Expense | $10,935.00MM | $13,583.00MM | $14,232.00MM |
| Income(Loss) | $6,899.00MM | $8,691.00MM | $12,402.00MM |
| Taxes | $938.00MM | $1,650.00MM | $2,169.00MM |
| Net Income(Loss)* | $5,955.00MM | $7,035.00MM | $10,255.00MM |
| Stockholders Equity | $39,143.00MM | $40,786.00MM | $48,667.00MM |
| Inventory | $5,424.00MM | $5,288.00MM | $6,557.00MM |
| Assets | $101,119.00MM | $104,035.00MM | $114,074.00MM |
| Operating Cash Flow | $10,345.00MM | $11,861.00MM | $14,575.00MM |
| Capital expenditure | $3,778.00MM | $4,586.00MM | $5,905.00MM |
| Investing Cash Flow | $-4,064.00MM | $-7,980.00MM | $-6,808.00MM |
| Financing Cash Flow | $-6,567.00MM | $-3,996.00MM | $-7,544.00MM |
| Earnings Per Share** | $3.81 | $4.54 | $6.62 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.